Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

16 Followers

BIOCON Stock Chart & Stats

₹433.70

₹2.60(0.60%)

At close: Jul 27 4:00 PM EDT

₹433.70

₹2.60(0.60%)

Day’s Range― - ―

52-Week Range₹337.20 - ₹447.00

Previous CloseN/A

Volume2.57M

Average Volume (3M)208.50K

Market Cap

₹674.12B

Enterprise Value₹828.93K

Total Cash (Recent Filing)₹28.33B

Total Debt (Recent Filing)₹155.51B

Price to Earnings (P/E)122.2

Beta0.69

Next Earnings

Nov 05, 2026

EPS Estimate

0.99

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)3.40

Shares Outstanding1,629,694,100

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)6.94

Revenue Forecast (FY)₹194.54B

Bulls Say, Bears Say

Bulls Say

Diversified Biopharma ModelBiocon’s mix of biosimilars, generic formulations and biologics services provides durable revenue diversification across products and clients. This reduces single-product risk, supports cross-segment scale economics and positions the company to capture structural growth in biologics, diabetes and oncology markets.

Sustained Revenue GrowthConsistent multi-year revenue expansion indicates continued market adoption and commercial traction of products and services. Durable top-line growth helps amortize fixed manufacturing costs, supports R&D and platform reinvestment, and underpins long-term capacity utilization and scale benefits.

Improving LeverageA materially lower debt-to-equity ratio enhances financial resilience and lowers interest burden, giving management more flexibility to fund commercialization, R&D or capex without excessive refinancing risk. Improved leverage supports longer-term strategic optionality and credit profile stability.

Bears Say

Sharp Margin CompressionA large decline in gross and net margins signals weaker pricing, adverse mix, higher costs or one-offs that materially reduce underlying profitability. Sustained margin erosion undermines the firm’s ability to generate surplus cash for reinvestment, R&D, and shareholder returns over the medium term.

Deteriorating Cash GenerationNegative free cash flow and a sharp fall in operating cash flow indicate earnings are not converting into cash. This reduces internal funding for capex, commercialization and debt servicing, increasing reliance on external financing and constraining strategic initiatives over the next several quarters.

Very Low Return On EquityAn ROE near 1% shows the company is generating minimal returns on shareholder capital despite revenue scale. Persistently low ROE reflects weak earnings quality and limits long-term value creation, pressuring capital allocation choices and investor confidence if structural improvement is not achieved.

Biocon Limited News

Biocon Shareholders Strongly Back 2026 Financials at 48th AGM

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited, a leading Indian biopharmaceutical company,...

15d ago

Biocon schedules Q1 FY27 earnings call and shares investor presentation

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has notified stock exchanges that it will...

17d ago

Biocon Wins Health Canada Approval for Yesintek Ustekinumab Autoinjector Pen

Biocon Limited ( ($IN:BIOCON) ) has issued an announcement. Biocon’s Canadian subsidiary has received Health Canada’s Notice of...

25d ago

Biocon makes Biocon Biologics a wholly owned unit via share swap

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has acquired 11,536,956 equity shares of its...

2M ago

Biocon Makes Biocon Biologics Wholly Owned Via Preferential Share Issue

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has completed the acquisition of...

2M ago

Biocon Closes Insider Trading Window Ahead of June Quarter Results

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has announced the closure of its trading...

2M ago

Biocon Deepens Malaysia Diabetes Push as Partner Wins MYR 225 Million Insulin Tenders

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon has reinforced its presence in Malaysia’s diabetes care...

2M ago

Biocon Sets Final Dividend and Outlines TDS Rules for FY 2025-26 Payout

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has informed shareholders that its board has...

2M ago

Biocon Subsidiary Wins Health Canada Nod for Antifungal Micafungin Injection

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a subsidiary of Biocon...

3M ago

Biocon Seeks Shareholder Nod for Leadership Changes and Preferential Share Issue via E-Voting

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited has initiated a postal ballot...

4M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹337.20 and its highest was ₹447.00 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹674.12B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on Aug 05, 2026. The company reported ₹0.87 earnings per share for the quarter, missing the consensus estimate of ₹1.005 by -₹0.135.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 0.99.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,629,694,100 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹0.87 in its last earnings report, missing expectations of ₹1.005. Following the earnings report the stock price went down -0.035%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.